Search

Your search keyword '"RIZZELLO, F."' showing total 47 results
Start Over Author "RIZZELLO, F." Publisher elsevier b.v.
47 results on '"RIZZELLO, F."'

17. P230 Adalimumab in active ulcerative colitis: A “real-life” observational study

Author

Armuzzi, A., Biancone, L., Daperno, M., Coli, A., Annese, V., Ardizzone, S., Balestrieri, P., Bossa, F., Castiglione, F., Cicala, M., Danese, S., D'Incà, R., Dulbecco, P., Feliciangeli, G., Fries, W., Genise, S., Gionchetti, P., Gozzi, S., Kohn, A., Lorenzetti, R., Milla, M., Onali, S., Orlando, A., Papparella, L.G., Pugliese, D., Renna, S., Ricci, C., Rizzello, F., Sostegni, R., Guidi, L., and Papi, C.

Published
2012
Full Text
View/download PDF

18. In vivo association to human colon of Lactobacillus paracasei B21060: Map from biopsies.

Author

Morelli, L., Garbagna, N., Rizzello, F., Zonenschain, D., and Grossi, E.

Subjects
LACTOBACILLUS, CLINICAL pathology, GASTROINTESTINAL mucosa, ANTIBACTERIAL agents
Abstract

Abstract: Background: Adhesion to the intestinal mucosa is one of the main suitable properties for probiotic bacteria. Several in vitro studies have been published, but a very few data are available about the in vivo adhesion to intestinal surfaces of probiotics. Moreover, there are no data regarding the distribution of a probiotic strain along the entire intestine. Aim: The present study aimed to preliminary evaluate the intestinal recovery of a new synbiotic formulation containing Lactobacillus paracasei B21060. Methods: Seven volunteers participated in the study. Subjects assumed three times a day for 15 days a sachet with a synbiotic preparation containing 5×109 CFUs of Lactobacillus paracasei strain B21060. Samples were recovered from the faeces and from the cecum, transverse, descending and sigmoid colon. Results: Identification at strain level showed that following administration, strain B21060 could be recovered from all sampled sites (except in one subject), representing 66.6% of the total vancomycin insensitive CFUs isolated from faecal samples, and 74.7% isolated from colonic samples. Conclusions: Our results demonstrate that Lactobacillus paracasei B21060 probiotic strain is able to temporarily associate throughout the different sites of the entire intestinal tract. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

19. Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study.

Author

Orlando, A., Colombo, E., Kohn, A., Biancone, L., Rizzello, F., Viscido, A., Sostegni, R., Benazzato, L., Castiglione, F., Papi, C., Meucci, G., Riegler, G., Mocciaro, F., Cassinotti, A., Cosintino, R., Geremia, A., Morselli, C., Angelucci, E., Lavagna, A., and Rispo, A.

Subjects
FISTULA, HUMAN abnormalities, TUMORS, CYTOKINES
Abstract

Abstract: Background.: Almost 20% of patients with active Crohn''s disease are refractory to conventional therapy. Infliximab is a treatment of proven efficacy in this group of patients and it is not clear which variables predict a good response. Aims.: To evaluate the role of infliximab looking at the predictors of response in a large series of patients with Crohn''s disease. Patients and methods.: Five hundred and seventy-three patients with luminal refractory Crohn''s disease (Crohn''s Disease Activity Index (CDAI)>220–400) (312 patients) or with fistulising disease (190 patients) or both of them (71 patients) were treated with a dose of 5mg/kg in 12 Italian referral centres. The primary endpoints of the study were clinical response and clinical remission for luminal refractory and fistulising disease. We evaluated at univariable and multivariable analysis the following variables: number of infusions, sex, age at diagnosis, smoking habit, site of disease, previous surgery, extraintestinal manifestations and concomitant therapies, and type of fistulas. Results.: Patients with luminal refractory disease: 322 patients (84.1%) had a clinical response and 228 (59.5%) reached clinical remission. Patients with fistulising disease: 187 patients (72%) had a reduction of 50% of the number of fistulas and in 107 (41%) a total closure of fistulas was observed. For luminal disease, single infusion (OR 0.49, 95% CI 0.28–0.86) and previous surgery (OR 0.53, 95% CI 0.30–0.93) predicted a worse response for fistulising disease. Other fistulas responded worse than perianal fistulas (OR 0.57, 95% CI 0.303–1.097). Conclusion.: In Crohn''s disease infliximab is effective in luminal refractory and in fistulising disease. A single infusion and previous surgery predicted a worse response in luminal disease whereas perianal fistulas predicted a better response than other type of fistulas. [Copyright &y& Elsevier]

Published
2005
Full Text
View/download PDF

45. Medical treatment and management of severe ulcerative colitis.

Author

Rizzello, F., Campieri, M., Tambasco, R., Straforini, G., Brugnera, R., Poggioli, G., and Gionchetti, P.

Subjects
IMMUNOSUPPRESSIVE agents, ULCERATIVE colitis, MEDICAL care, CYCLOSPORINE
Abstract

Abstract: Severe colitis is a life-threatening complication of ulcerative colitis. Early recognition of the severity of the colitis and intensive treatment and monitoring have all contributed to improved outcome. Since their introduction in the 1950s, corticosteroids are the first line therapy for severe active ulcerative colitis (UC). Several prognostic parameters (such as stools movement per day, C-reactive protein, increased amount of intestinal gas or small bowel dilation, hypoalbuminemia, fever, etc.) help the physician to quickly introduce infliximab or cyclosporine or to refer the patient to the surgeon. This decision requires a careful evaluation of the patient and a medical/surgical team. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

47. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: Adhesion properties, competition against enteropathogens and modulation of IL-8 production

Author

Candela, M., Perna, F., Carnevali, P., Vitali, B., Ciati, R., Gionchetti, P., Rizzello, F., Campieri, M., and Brigidi, P.

Subjects
*PROBIOTICS, *IMMUNOREGULATION, *LACTOBACILLUS, *BIFIDOBACTERIUM
Abstract

Abstract: The human intestinal microbiota plays a pivotal role in human nutrition and health by promoting the supply of nutrients, preventing pathogen colonization and shaping and maintaining normal mucosal immunity. The depletion of the individual microbiota can result in a higher susceptibility to enteropathogenic bacteria infection. In order to reduce this risk, the use of food supplements containing probiotic bacteria has been recently addressed. In this paper, we investigate the protective role toward enteropathogen infection of probiotic strains belonging to Lactobacillus and Bifidobacterium. According to our experimental data, Lactobacillus acidophilus Bar13, L. plantarum Bar10, Bifidobacterium longum Bar33 and B. lactis Bar30 were effective in displacing the enteropathogens Salmonella typhimurium and Escherichia coli H10407 from a Caco-2 cell layer. Moreover, L. acidophilus Bar13 and B. longum Bar33 have been assessed for their immunomodulatory activity on IL-8 production by HT29 cells. Both strains showed the potential to protect enterocytes from an acute inflammatory response. These probiotic strains are potential candidates for the development of new functional foods helpful in counteracting enteropathogen infections. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results